Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06125652
PHASE1/PHASE2

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Sponsor: Xuzhou Medical University

View on ClinicalTrials.gov

Summary

To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.

Official title: Application of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2023-11-04

Completion Date

2027-01-01

Last Updated

2023-11-09

Healthy Volunteers

No

Interventions

DRUG

anti Tim-3/CD123 CAR-T cell therapy

Enrolled patients will receive prespecified dose of autologous CAR-T cells.

Locations (1)

Kailin Xu

Xuzhou, Jiangsu, China